Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
apitegromab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6237 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Jul 28, 2021: Acceleron announces second quarter 2021 REBLOZYL net sales
Jun 18, 2021: Scholar Rock to present Apitegromab TOPAZ phase 2 trial results highlighting pharmacokinetic (PK) and pharmacodymic (PD) data at the 2021 European Academy of Neurology Congress
Jun 11, 2021: Scholar Rock presents TOPAZ phase 2 data showing the transformative potential of apitegromab in patients with type 2 and 3 Spil Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
Jun 11, 2021: Bristol Myers Squibb and Acceleron present first results from phase 2 beyond study of Reblozyl (Luspatercept-aamt) In adults with non-transfusion dependent (NTD) beta thalassemia
Jun 07, 2021: Scholar Rock to present Apitegromab clinical data from the TOPAZ phase 2 trial in patients with Type 2 and 3 Spil Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
May 24, 2021: Scholar Rock receives fast track desigtion from the U.S. FDA for apitegromab for the treatment of patients with spil muscular atrophy
May 12, 2021: Acceleron announces presentations on REBLOZYL (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
May 11, 2021: Scholar Rock announces publication of phase 1 clinical trial data evaluating Apitegromab in healthy volunteers in the jourl Advances in Therapy
Apr 26, 2021: Scholar Rock announces issuance of U.S. Patent broadly relevant to inhibitors of myostatin activation
Apr 06, 2021: Scholar Rock announces positive 12-month top-line results from the TOPAZ phase 2 clinical trial evaluating apitegromab in patients with type 2 and type 3 spil muscular atrophy (SMA)
Mar 17, 2021: Scholar Rock announces issuance of U.S. patent protecting add-on or combition therapy with a myostatin inhibitor for the treatment of spil muscular atrophy
Mar 15, 2021: Scholar Rock presents TOPAZ interim alysis data for Apitegromab in spil muscular atrophy at the 2021 Muscular Dystrophy Association (MDA) virtual clinical & scientific conference
Feb 16, 2021: Health Cada approves REBLOZYL (luspatercept), new class of treatment for adult patients living with myelodysplastic syndromes
Feb 04, 2021: Acceleron announces fourth quarter and full year 2020 Reblozyl net sales
Nov 04, 2020: Rocket Pharmaceuticals to present data from its Fanconi Anemia, leukocyte adhesion deficiency-i and pyruvate kise deficiency programs at the 62nd American Society of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Acceleron Pharma Inc, 2021
Pipeline by Biogen Inc, 2021
Pipeline by Bioleaders Corp, 2021
Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Pipeline by PeptiDream Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Scholar Rock Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021